While various cues initiate the cellular conversion of fibroblasts to myofibroblasts, TGFβ1 (transforming growth factor β1) is considered a master regulator.9 However, antifibrotic therapeutic approaches based on TGFβ1 inhibition have side effects due to the pleiotropic roles of this cytokine, especially in cancer and inflammation.10,11 Thus, unraveling the fibroblast-specific footprint of TGFβ1 signaling is an important step toward the identification of novel downstream drivers of cardiac disease. This evidence concerns the gene TGFB1 and cancer.